Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

185
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
185
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

1.1K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.1K
Glucose Transporters01:27

Glucose Transporters

22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Proteoglycans01:05

Proteoglycans

3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

980
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
980

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health-related quality of life outcomes with nipocalimab versus placebo in generalized myasthenia gravis: an analysis of the Vivacity-MG3 study.

Journal of neurology·2026
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double‑blind, placebo‑controlled, phase 3 trial (ADAPT).

Journal of neurology·2026
Same author

Natural history of cardiac involvement in women carrying pathogenic DMD gene variants: a 7-year longitudinal study.

Journal of neurology·2026
Same author

Prevalence and characteristics of patients with seronegative myasthenia gravis.

Journal of neurology·2026
Same author

Variability in Liver Disease Progression and Outcomes in Glycogen Storage Disease Type IV.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same journal

Integrating sexual health into care for patients with cancer and chronic illness.

Nature reviews. Disease primers·2026
Same journal

Chronic graft-versus-host disease.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Jul 17, 2025

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination
04:50

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination

Published on: February 8, 2022

5.3K

Glycogen storage diseases.

William B Hannah1, Terry G J Derks2, Mitchell L Drumm3

  • 1Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, USA. wbh16@case.edu.

Nature Reviews. Disease Primers
|September 7, 2023
PubMed
Summary
This summary is machine-generated.

Glycogen storage diseases (GSDs) are rare genetic disorders affecting glycogen metabolism. This primer details their diverse clinical features, diagnosis, management, and emerging therapies for improved patient outcomes.

More Related Videos

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

21.3K
Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

28.5K

Related Experiment Videos

Last Updated: Jul 17, 2025

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination
04:50

The Extraction of Liver Glycogen Molecules for Glycogen Structure Determination

Published on: February 8, 2022

5.3K
Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
09:42

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining

Published on: December 23, 2014

21.3K
Biochemical Titration of Glycogen In vitro
07:16

Biochemical Titration of Glycogen In vitro

Published on: November 24, 2013

28.5K

Area of Science:

  • Biochemistry
  • Genetics
  • Metabolic Disorders

Background:

  • Glycogen storage diseases (GSDs) are rare, inherited metabolic disorders caused by defects in glycogen synthesis or degradation.
  • These conditions manifest with multi-organ clinical features, primarily affecting the liver and muscles.

Purpose of the Study:

  • To provide a comprehensive overview of GSDs, covering their epidemiology, biochemistry, and disease mechanisms.
  • To outline current diagnostic approaches and management strategies, including surveillance, dietary interventions, and specific therapies.
  • To discuss the impact of GSDs on quality of life and highlight future research directions and novel therapeutic avenues.

Main Methods:

  • Review of existing literature and clinical guidelines on GSDs.
  • Description of diagnostic tools such as phenotypic characterization, biomarkers, imaging, genetic testing, enzyme analysis, and histology.
  • Summary of management strategies including surveillance, dietary modifications, exercise, and specific treatments like enzyme replacement therapy and SGLT2 inhibitors.

Main Results:

  • GSDs present with diverse clinical manifestations and require tailored diagnostic and management plans.
  • Established guidelines exist for some GSDs, aiding in diagnosis and treatment.
  • Emerging therapies and ongoing clinical trials offer promise for improving the natural course, morbidity, and mortality associated with GSDs.

Conclusions:

  • Accurate diagnosis and comprehensive management are crucial for improving the quality of life and outcomes for patients with GSDs.
  • Continued research into the natural history and novel therapeutics is essential for advancing GSD care.
  • The development of patient-centered outcomes is needed to better assess the impact of interventions on quality of life.